Invitrogen is buying out CellzDirect in a $57 million cash deal. CellzDirect provides R&D operations hepatocyte-based cell products and other services used to test new drugs. Primary human hepatocytes can be used to predict a compound's effects on enzymatic metabolism in the liver, helping to avoid trial failures. CellzDirect was set up seven years ago and has facilities in North Carolina and Austin.
- check out the release for more info